Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis.

Fiche publication

Date publication

juillet 2018

Journal

Current medical research and opinion

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HERBRECHT Raoul

Tous les auteurs :
Herbrecht R, Kuessner D, Pooley N, Posthumus J, Escrig C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30022696

Résumé

Voriconazole, amphotericin B (AmB) formulations, and isavuconazole are all included in guideline recommendations for treatment of patients with invasive aspergillosis (IA) but the relative efficacy of isavuconazole versus AmB formulations has not been directly compared. We aimed to estimate the relative efficacy of isavuconazole compared with AmB deoxycholate (AmB-D), liposomal AmB (L-AmB), and voriconazole for the treatment of patients with proven/probable IA.